Results 51 to 60 of about 2,243,298 (271)
Oncology Letters, 2019 Due to its rapid progression, metastasis and resistance to chemotherapy, pancreatic cancer is one of the most malignant tumor types to affect the digestive system. Gemcitabine chemotherapy is typically the first choice of treatment for advanced pancreatic cancer; however, chemoresistance is a major obstacle to successful treatment.
Yu, Yue +4 more
openaire +3 more sources
Hepatology, EarlyView., 2022 Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou +13 more
wiley +1 more source
Frontiers in Oncology, 2021 ObjectivePancreatic cancer is one of the most lethal human malignancies. Gemcitabine is widely used to treat pancreatic cancer, and the resistance to chemotherapy is the major difficulty in treating the disease.
Congjun Zhang +7 more
doaj +1 more source
Resistance mechanisms to gemcitabine in pancreatic cancer [PDF]
, 2021 Treatment of pancreatic cancer involves combinations of therapeutics including use of the chemotherapy agent gemcitabine. This thesis aimed to identify gemcitabine resistance mechanisms in pancreatic cancer and so enable discovery of biomarkers to tailor chemotherapy.
openaire +1 more source
Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: Pretreatment levels or kinetics during chemotherapy? [PDF]
, 2007 Background: The carbohydrate antigen 19-9 (CA 19-9) is currently the most widely used serum tumor marker in pancreatic cancer (PC). CA 19-9 pretreatment levels as well as CA 19-9 kinetics during systemic chemotherapy can provide prognostic information ...
Holdenrieder, Stefan +5 more
core +1 more source
Bangladesh Journal of PharmacologyGemcitabine is a common first-line chemotherapy agent, but gemcitabine resistance is a clinical challenge for pancreatic ductal adenocarcinoma patients.
Hao Yu +5 more
doaj +1 more source
Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer
Cancers, 2022 Resistance to treatments is one of the leading causes of cancer therapy failure. Oxaliplatin is a standard chemotherapy used to treat metastatic colorectal cancer. However, its efficacy is greatly reduced by the development of resistances. In a previous study, we deciphered the mechanisms leading to oxaliplatin resistance and highlighted the roles ...
Chocry, Mathieu +5 more
openaire +2 more sources
Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer [PDF]
, 2012 Although gemcitabine is the standard chemotherapeutic drug for treatment of pancreatic cancer, almost all patients eventually develop resistance to this agent.
Kuang, Shihuan +9 more
core +2 more sources
Molecular mechanisms of drug resistance, invasion and metastasis in pancreatic carcinoma [PDF]
, 2008 The research outlined in this thesis aims to further our knowledge of the biological characteristics underlying the aggressive behaviour by which pancreatic cancer invades and metastasises at an early stage and is refractory to most chemotherapeutic ...
Walsh, Naomi
core +2 more sources
A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy. [PDF]
PLoS ONE, 2013 Gemcitabine is among the most efficacious and widely used antimetabolite agents. Its molecular targets are ribonucleotide reductase M1 (RRM1) and elongating DNA.
Jun Zhou +6 more
doaj +1 more source